Clinical Trial Results: Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating point-of-care pharmacogenomic testing to optimize isoniazid dosing for tuberculosis prevention.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis Infection

Drugs mentioned

• ISONIAZID (ISONIAZID)

Snippet

Sponsor: Stanford University | Conditions: Tuberculosis Infection, Isoniazid Adverse Reaction | Phase 1 | Status: COMPLETED | Results posted: 2026-06-15